The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer
Abstract
Purpose: Pain from castration-refractory prostate cancer (CRPC) bone metastases is a common event. Although it is assumed that pain represents an adverse prognostic factor, this variable has not been extensively evaluated. The objective of this study was to determine whether men with CRPC who had higher pain interference scores at baseline had worse clinical outcomes compared with men who had lower pain scores. Patients and Methods: Data from three randomized phase III multicenter trials conducted by the Cancer and Leukemia Group B from 1992 to 1998 were combined. Eligible patients had progressive CRPC adenocarcinoma of the prostate, an Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate hematologic, renal, and hepatic functions. Seven items from the Brief Pain Inventory were used to assess the impact of pain on a range of daily activities and quality of life, each rated on a scale from 0 to 10. Results: In 599 men, the median pain interference scores was 17 (interquartile range, 4 to 34), and 38% of the men had opioid analgesic use at baseline. There was a statistically significant association between pain interference scores and risk of death. The median survival times were 17.6 months (95% CI, 16.1 to 19.1 months) and 10.2 months (95% CI, 8.6 to 11.3 months; P < .001) in men with low (< 17) and high (≥ 17) pain scores, respectively. Pain was inversely associated with likelihood of prostate-specific antigen decline, objective response, and time to bone progression. Conclusion: This analysis demonstrates that pain is a statistically significant predictor of overall survival in men with metastatic CRPC. These results need to be validated prospectively in future phase III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Cited by
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationAdverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., Appawu, M., Iasonos, A., Atkinson, T., Goldfarb, S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp386 · Cited by 624
Pienta, K. J., Machiels, J.-P., Schrijvers, D., Alekseev, B., Shkolnik, M., Crabb, S. J., Li, S., Seetharam, S., Puchalski, T. A., Takimoto, C., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9869-8 · Cited by 412
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Saad, F., Carles, J., Gillessen, S., Heidenreich, A., Heinrich, D., Gratt, J., Lévy, J., Miller, K., Nilsson, S., Petrenciuc, O., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30173-5 · Cited by 294
Metadata
- Authors
- Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., & Small, E. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-20
- Volume
- 26
- Issue
- 15
- Pages
- 2544-2549
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142200772
- Cited by
- 193
- References
- 2
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2007.15.0367
- The paper
- Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., & Small, E. J. (2008). Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.0367
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.